News
BPMC
112.99
-0.62%
-0.70
Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential
Seeking Alpha · 2d ago
Some Confidence Is Lacking In Blueprint Medicines Corporation's (NASDAQ:BPMC) P/S
Blueprint Medicines Corporation (NASDAQ:BPMC) has a price-to-sales ratio of 25.9x. The company's revenue has fallen 65% in three years and is expected to grow less than the industry. The P/S ratio is higher than the average for the Biotech industry. Blueprint Medicines could be paying too much for the stock as it's growing revenue less than other companies.
Simply Wall St · 3d ago
Piper Sandler Keeps Their Hold Rating on Blueprint Medicines (BPMC)
TipRanks · 3d ago
Weekly Report: what happened at BPMC last week (0715-0719)?
Weekly Report · 4d ago
Stifel Nicolaus Remains a Buy on Blueprint Medicines (BPMC)
TipRanks · 07/19 12:16
ClearBridge Small Cap Growth Strategy Q2 2024 Commentary
ClearBridge Small Cap Growth Strategy Q2 2024 Commentary. Small cap stocks are enduring their largest period of underperformance versus large caps to start a year in the last 51 years. Volatility in the Russell 2000 Growth Index was only down 2.9% in the second quarter of 2024.
Seeking Alpha · 07/17 14:40
Blueprint Medicines: Overdue For A Breather
Seeking Alpha · 07/16 14:20
Oppenheimer’s best SMID-cap ideas: AI, health, obesity drugs, and more
Oppenheimer’s best SMID-cap ideas: AI, health, obesity drugs, and more. The ideas exhibit a bullish technical trend. Analysts updated their best SMid-cap. Ideas for the year, providing exposure to high-growth themes, such as artificial intelligence.
Seeking Alpha · 07/15 18:00
Weekly Report: what happened at BPMC last week (0708-0712)?
Weekly Report · 07/15 09:25
Blueprint Medicines Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 07/12 17:27
Blueprint Medicines Price Target Raised to $115.00/Share From $110.00 by Morgan Stanley
Dow Jones · 07/12 17:27
Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $115
Benzinga · 07/12 17:18
Blueprint Medicines (BPMC) Receives a Hold from Morgan Stanley
TipRanks · 07/12 12:25
Oppenheimer’s top SMID ideas within high-growth themes
Oppenheimer’s top SMID ideas within high-growth themes. These stocks are high-conviction “SMID-cap” ideas for 2024 with a market cap of $1B to $10B. Oppenheimer research analysts outlined the top small-cap and mid-cap stocks that have exposure to several high- growth themes.
Seeking Alpha · 07/10 16:46
Oppenheimer’s best ‘SMID-cap’ ideas for 2024
Oppenheimer’s best ‘SMID-cap’ ideas for 2024. Both the S&P 400 and the s&P 600 are maintaining above prior breakout levels and their 200-day average. Mid-cap growth is the analysts’ top rotation idea.
Seeking Alpha · 07/10 15:35
Biotech Stocks 2024 Second Half Outlook - Buy Biotechs
Biotech indexes lagged broader market indexes in the first half of 2024. Biotech valuations are closely tied to the Fed's interest rate policy and are highly correlated to the 10-year yield. Inflation is likely to trend lower, and the Fed is expected to cut rates in September. The second half of 2024 holds potential for biotech stocks to break out of their consolidation.
Seeking Alpha · 07/09 11:00
Blueprint Medicines Price Target Raised to $125.00/Share From $114.00 by Oppenheimer
Dow Jones · 07/08 13:01
Blueprint Medicines Is Maintained at Outperform by Oppenheimer
Dow Jones · 07/08 13:01
Oppenheimer Maintains Outperform on Blueprint Medicines, Raises Price Target to $125
Benzinga · 07/08 12:50
BLUEPRINT MEDICINES <BPMC.O>: OPPENHEIMER RAISES TARGET PRICE TO $125 FROM $114
Reuters · 07/08 12:02
More
Webull provides a variety of real-time BPMC stock news. You can receive the latest news about Blueprint Medicines Corp through multiple platforms. This information may help you make smarter investment decisions.
About BPMC
Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.